203.71

2.24% -4.67

Pre-market: 205.25 1.54 +0.76%

Abbvie Inc (ABBV)

Overview News Price History Option Chain Financials Why ABBV Down? Discussions Forecast Dividend History

Abbvie Inc stock is traded at $203.71, with a volume of 5.77M. It is down -2.24% in the last 24 hours and down -0.66% over the past month. AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.

Previous Close:

$208.38

Open:

$207.94

24h Volume:

5.77M

Relative Volume:

0.82

Market Cap:

$360.31B

Revenue:

$61.16B

Net Income/Loss:

$4.19B

P/E Ratio:

86.27

EPS:

2.3614

Net Cash Flow:

$17.82B

1W Performance:

-1.34%

1M Performance:

-0.66%

6M Performance:

-12.22%

1Y Performance:

+17.76%

1-Day Range:

$202.84

$208.33

1-Week Range:

$202.84

$212.35

52-Week Range:

$168.54

$244.81

Abbvie Inc Stock (ABBV) Company Profile

Name

Abbvie Inc

Sector

Healthcare (1114)

Industry

Drug Manufacturers - General (20)

Phone

(847) 932-7900

Address

1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL

Employee

57,000

Twitter

@abbvie

Next Earnings Date

2026-04-29

Latest SEC Filings

ABBV's Discussions on Twitter

Compare ABBV vs LLY, JNJ, AZN, MRK

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ABBV Abbvie Inc	203.71	368.57B	61.16B	4.19B	17.82B	2.3614
LLY Lilly Eli Co	919.90	828.17B	65.18B	20.64B	5.96B	22.59
JNJ Johnson Johnson	230.69	564.05B	96.36B	21.04B	19.70B	8.6488
AZN Astrazeneca Plc	200.69	317.61B	58.80B	10.24B	8.98B	3.2788
MRK Merck Co Inc	117.10	294.09B	64.93B	18.26B	12.36B	7.2751

Abbvie Inc Stock (ABBV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-25-26	Initiated	RBC Capital Mkts	Outperform
Feb-20-26	Initiated	Barclays	Overweight
Jan-08-26	Downgrade	Wolfe Research	Outperform → Peer Perform
Jan-07-26	Resumed	UBS	Neutral
Dec-10-25	Upgrade	HSBC Securities	Hold → Buy
Nov-13-25	Initiated	Scotiabank	Sector Outperform
Nov-04-25	Downgrade	DZ Bank	Buy → Hold
Oct-14-25	Downgrade	Erste Group	Buy → Hold
Oct-01-25	Downgrade	HSBC Securities	Buy → Hold
Sep-17-25	Upgrade	Berenberg	Hold → Buy
Aug-12-25	Resumed	Piper Sandler	Overweight
Aug-07-25	Upgrade	Daiwa Securities	Neutral → Outperform
May-14-25	Downgrade	Citigroup	Buy → Neutral
Apr-22-25	Initiated	Cantor Fitzgerald	Overweight
Dec-10-24	Resumed	BofA Securities	Neutral
Dec-05-24	Downgrade	Daiwa Securities	Outperform → Neutral
Nov-22-24	Upgrade	Leerink Partners	Market Perform → Outperform
Nov-15-24	Initiated	Wolfe Research	Outperform
Nov-04-24	Upgrade	Argus	Hold → Buy
Oct-17-24	Initiated	Bernstein	Mkt Perform
Jun-05-24	Upgrade	HSBC Securities	Hold → Buy
May-17-24	Initiated	Cantor Fitzgerald	Overweight
Jan-29-24	Upgrade	William Blair	Mkt Perform → Outperform
Dec-18-23	Downgrade	HSBC Securities	Buy → Hold
Dec-11-23	Upgrade	Goldman	Neutral → Buy
Nov-09-23	Initiated	Deutsche Bank	Hold
Oct-30-23	Upgrade	Barclays	Equal Weight → Overweight
Oct-20-23	Resumed	UBS	Neutral
Sep-29-23	Initiated	Raymond James	Outperform
Jul-25-23	Initiated	William Blair	Mkt Perform
Jul-14-23	Initiated	HSBC Securities	Buy
Apr-05-23	Downgrade	Argus	Buy → Hold
Mar-01-23	Initiated	Guggenheim	Buy
Feb-22-23	Downgrade	Wolfe Research	Outperform → Peer Perform
Feb-10-23	Upgrade	SVB Securities	Underperform → Market Perform
Nov-18-22	Initiated	Credit Suisse	Outperform
Nov-08-22	Downgrade	Societe Generale	Buy → Hold
Aug-01-22	Downgrade	Atlantic Equities	Overweight → Neutral
May-23-22	Initiated	SVB Leerink	Underperform
May-06-22	Downgrade	Daiwa Securities	Outperform → Neutral
Apr-06-22	Resumed	Morgan Stanley	Overweight
Feb-28-22	Downgrade	UBS	Buy → Neutral
Feb-03-22	Reiterated	BMO Capital Markets	Outperform
Feb-03-22	Reiterated	Barclays	Equal Weight
Feb-03-22	Reiterated	BofA Securities	Neutral
Feb-03-22	Reiterated	Goldman	Neutral
Jan-13-22	Initiated	Redburn	Buy
Jan-12-22	Reiterated	BMO Capital Markets	Outperform
Dec-09-21	Resumed	Wells Fargo	Overweight
Nov-23-21	Upgrade	Societe Generale	Hold → Buy
Jul-27-21	Resumed	Truist	Buy
Apr-07-21	Resumed	RBC Capital Mkts	Outperform
Nov-10-20	Resumed	Bernstein	Outperform
Sep-29-20	Initiated	Berenberg	Hold
Jun-23-20	Upgrade	Atlantic Equities	Neutral → Overweight
Jun-09-20	Upgrade	Wolfe Research	Peer Perform → Outperform
Jun-02-20	Upgrade	Argus	Hold → Buy
May-18-20	Resumed	BofA/Merrill	Neutral
May-12-20	Upgrade	JP Morgan	Neutral → Overweight
May-11-20	Resumed	Morgan Stanley	Overweight
Apr-20-20	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Mar-23-20	Downgrade	Societe Generale	Buy → Hold
Feb-27-20	Initiated	Barclays	Equal Weight
Feb-06-20	Initiated	Mizuho	Buy
Jan-07-20	Initiated	RBC Capital Mkts	Sector Perform
Dec-26-19	Reiterated	Cowen	Outperform
Sep-26-19	Upgrade	Citigroup	Neutral → Buy
Aug-20-19	Upgrade	Piper Jaffray	Neutral → Overweight
Jun-27-19	Upgrade	Wolfe Research	Underperform → Peer Perform
Jun-26-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
May-28-19	Initiated	Goldman	Neutral
Apr-29-19	Upgrade	BMO Capital Markets	Underperform → Market Perform

View All

Abbvie Inc (ABBV)

Abbvie Inc Stock (ABBV) Company Profile

Compare ABBV vs LLY, JNJ, AZN, MRK

Abbvie Inc Stock (ABBV) Upgrades & Downgrades

Abbvie Inc Stock (ABBV) Latest News

Biologics Market: Share and Outlook Driven by Roche, Amgen, and AbbVie Leading Advanced Therapeutics - openPR.com

Here's Why AbbVie (ABBV) Fell More Than Broader Market - Yahoo Finance

AbbVie and BioLabs Team Up to Support Life Sciences Innovation in Canada - Investing News Network

AbbVie Sponsors New BioLabs Facility in Toronto - marketscreener.com

Will AbbVie's Oncology Franchise Weigh on Q1 Top-line Growth? - qz.com

AbbVie And BioLabs Team Up To Support Life Sciences Innovation In Canada - TradingView

AbbVie and BioLabs Team Up to Support Life Sciences Innovation in Canada – Company Announcement - Financial Times

Nxera Pharma Co., Ltd. Reaches Third R&D Milestone Under Collaboration with Abbvie - marketscreener.com

Nxera to receive $10 million milestone from AbbVie deal - The Pharma Letter

AbbVie Makes $10 Million Milestone Payment to Nxera Pharma Under Collaboration - marketscreener.com

The Zacks Analyst Blog Microsoft, AbbVie, BHP, CBL & Associates Properties and IRIDEX - Zacks Investment Research

Top Dividend Stocks for Income: AbbVie & Enbridge Analysis | 2026 MarketNews and Statistics - IndexBox

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases - GlobeNewswire Inc.

AbbVie (ABBV) Is One Of The Major Stock To Buy According To Wall Street - Insider Monkey

Lobbying Update: $180,000 of ABBVIE INC. lobbying was just disclosed - Quiver Quantitative

AbbVie Inc stock (US00287Y1091): Is its immunology dominance strong enough to unlock new upside? - AD HOC NEWS

ABBV Stock Quote Price and Forecast - CNN

Asset Management One Co. Ltd. Has $209.74 Million Stock Position in AbbVie Inc. $ABBV - MarketBeat

AbbVie Inc. (ABBV): A Bull Case Theory - MSN

AbbVie Inc. (NYSE:ABBV) Short Interest Update - MarketBeat

PBUThe Pension Fund of Early Childhood & Youth Educators's AbbVie Inc(ABBV) Holding History - GuruFocus

Top Analyst Reports for Microsoft, AbbVie & BHP - Yahoo Finance

Should you buy AbbVie stock before April 29? - MSN

AbbVie inks $745 million deal to develop pain medicines from Chinese drugmaker - Crain's Chicago Business

AbbVie Trades Below 50-Day and 200-Day SMA: How to Play the Stock - The Globe and Mail

AbbVie vs. Pfizer: One Pharma Dividend Has a Moat — The Other Is Praying for a Pipeline Hit - Yahoo Finance

DB&C Advisors, LLC's AbbVie Inc(ABBV) Holding History - GuruFocus

Merit Financial Group LLC Has $21.32 Million Stake in AbbVie Inc. $ABBV - MarketBeat

Pertzye Market Booming with Rapid Growth Through 2033| AbbVie • Nestlé Health Science • Solvay Pharmaceuticals - openPR.com

AE Wealth Management LLC Purchases 7,696 Shares of AbbVie Inc. $ABBV - MarketBeat

AbbVie, Inc. Trade Ideas — TURQUOISE:4ABD - TradingView

Portfolio Building Block World Pharma and Biotech Index ETF's AbbVie Inc(ABBV) Holding History - GuruFocus

Why AbbVie Is a No-Brainer Stock to Buy on the Dip - AOL.com

AbbVie Steps Deeper Into Obesity Market With New Phase 1 ABBV-295 Trial - TipRanks

AbbVie’s Head-to-Head Psoriasis Study Sets Up New Catalyst for ABBV Investors - TipRanks

ABBV: Abbott Laboratories Reports In-Line EPS and Strong Revenue Beat - GuruFocus

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), McKesson (MCK) and Regeneron (REGN) - The Globe and Mail

Nations Financial Group Inc. IA ADV Has $4.88 Million Stock Position in AbbVie Inc. $ABBV - MarketBeat

Lbp Am Sa Purchases 8,678 Shares of AbbVie Inc. $ABBV - MarketBeat

AbbVie eases the pain with $745m licensing deal - BioXconomy

Cwm LLC Boosts Holdings in AbbVie Inc. $ABBV - MarketBeat

Diversified Management Inc. Takes Position in AbbVie Inc. $ABBV - MarketBeat

Adelphi Trust Co Makes New Investment in AbbVie Inc. $ABBV - MarketBeat

Operating expenses (excl. COGS) of AbbVie, Inc. – BSESOF:4AB - TradingView — Track All Markets

Fidelity SAI U.S. Quality Index Fund's AbbVie Inc(ABBV) Holding History - GuruFocus

Evercore ISI Tweaks AbbVie (ABBV) Estimates, Lowers Price Target Marginally - Yahoo Finance

Spectrum Asset Management Reduces AbbVie Stake - National Today

NSCLC Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | AbbVie, AstraZeneca and Daiichi Sankyo, Shanghai Henlius Biotech, Moderna Therapeutics/ Merck, BeyondSpring, Cullinan - Barchart.com

Morgan Stanley Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $270 - Moomoo

RemeGen (09995.HK) Receives USD650M Upfront Payment from AbbVie for RC148 - AASTOCKS.com

AbbVie Inc. $ABBV Shares Purchased by Farther Finance Advisors LLC - MarketBeat

Abbvie Inc Stock (ABBV) Financials Data

Revenue

Net Income

Cash Flow

EPS

Similar to ABBV